Total Payments
$298,972
2024 Payments
$856.85
Companies
18
Transactions
176
Payment Breakdown by Category
Consulting$202,496 (67.7%)
Other$71,843 (24.0%)
Travel$13,001 (4.3%)
Research$8,195 (2.7%)
Food & Beverage$3,438 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,496 | 45 | 67.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,843 | 20 | 24.0% |
| Travel and Lodging | $13,001 | 39 | 4.3% |
| Unspecified | $8,195 | 10 | 2.7% |
| Food and Beverage | $3,438 | 62 | 1.2% |
Payments by Type
General
$290,777
166 transactions
Research
$8,195
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $123,276 | 30 | $0 (2023) |
| Medtronic MiniMed, Inc. | $56,485 | 60 | $0 (2020) |
| Novo Nordisk AS | $22,748 | 8 | $0 (2021) |
| Eli Lilly and Company | $18,900 | 4 | $0 (2018) |
| Novo Nordisk Inc | $14,494 | 16 | $0 (2023) |
| Eisai Inc. | $12,748 | 13 | $0 (2020) |
| BioMarin Pharmaceutical Inc. | $11,411 | 3 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $10,332 | 10 | $0 (2019) |
| Ipsen Bioscience Inc | $9,000 | 1 | $0 (2022) |
| Medtronic, Inc. | $7,500 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $856.85 | 2 | Boehringer Ingelheim International GmbH ($856.85) |
| 2023 | $28,060 | 11 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,000) |
| 2022 | $24,276 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,000) |
| 2021 | $14,860 | 4 | Medtronic, Inc. ($7,500) |
| 2020 | $44,744 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($39,430) |
| 2019 | $74,389 | 63 | Boehringer Ingelheim Pharmaceuticals, Inc. ($24,846) |
| 2018 | $69,661 | 45 | Medtronic MiniMed, Inc. ($20,987) |
| 2017 | $42,125 | 33 | Novo Nordisk AS ($11,935) |
All Payment Transactions
176 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $617.89 | General |
| Category: DIABETES | ||||||
| 04/12/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $238.96 | General |
| Category: DIABETES | ||||||
| 12/31/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $564.38 | General |
| Category: DIABETES | ||||||
| 12/31/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $265.52 | General |
| Category: DIABETES | ||||||
| 10/11/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $265.52 | General |
| Category: DIABETES | ||||||
| 07/12/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $617.89 | General |
| Category: DIABETES | ||||||
| 07/12/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $265.52 | General |
| Category: DIABETES | ||||||
| 05/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 03/21/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 03/06/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 01/25/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,322.79 | General |
| Category: DIABETES | ||||||
| 01/25/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $507.94 | General |
| Category: DIABETES | ||||||
| 01/23/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 10/28/2022 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $276.10 | General |
| Category: DIABETES | ||||||
| 09/30/2022 | Ipsen Bioscience Inc | — | Consulting Fee | Cash or cash equivalent | $9,000.00 | General |
| 08/23/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 05/31/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 04/19/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: DIABETES | ||||||
| 11/24/2021 | Medtronic, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| 07/05/2021 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $1,360.00 | General |
| 03/15/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 02/16/2021 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 10/30/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: DIABETES | ||||||
| 10/29/2020 | Medtronic MiniMed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 09/16/2020 | Eisai Inc. | Belviq (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Nutrition and Weight Loss | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus? Injected Once Daily in Children and Ad | SANOFI-AVENTIS U.S. LLC | $2,089 | 2 |
| A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes | AstraZeneca UK Limited | $1,928 | 2 |
| EDITION JUNIOR | SANOFI-AVENTIS U.S. LLC | $1,504 | 2 |
| Multinational, cross-sectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients | SANOFI-AVENTIS U.S. LLC | $1,340 | 2 |
| 6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected Once Daily in Children and Adol | SANOFI-AVENTIS U.S. LLC | $804.00 | 1 |
| SAGE | SANOFI-AVENTIS U.S. LLC | $530.00 | 1 |
About Dr. William Tamborlane, MD
Dr. William Tamborlane, MD is a Pediatric Endocrinology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124001342.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Tamborlane, MD has received a total of $298,972 in payments from pharmaceutical and medical device companies, with $856.85 received in 2024. These payments were reported across 176 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($202,496).
Ad
Practice Information
- Specialty Pediatric Endocrinology
- Location New Haven, CT
- Active Since 11/22/2005
- Last Updated 04/06/2011
- Taxonomy Code 2080P0205X
- Entity Type Individual
- NPI Number 1124001342
Products in Payments
- TRADJENTA (Drug) $105,000
- Minimed 670G System (Device) $41,992
- JARDIANCE (Drug) $22,674
- Belviq (Drug) $12,748
- FIASP (Drug) $11,935
- Victoza (Drug) $11,809
- BMN 111 (Biological) $11,411
- TOUJEO (Drug) $8,607
- Tresiba (Drug) $6,649
- BYETTA (Drug) $1,928
- ADLYXIN (Drug) $1,726
- EMPAGLIFLOZIN (Drug) $250.00
- InPen (Device) $139.64
- FASENRA (Drug) $132.30
- Minimed 630G (Device) $100.93
- t-slim insulin pump (Device) $86.60
- OneTouch (Device) $74.29
- Minimed Paradigm Revel (Device) $51.96
- BAQSIMI (Drug) $23.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Endocrinology Doctors in New Haven
Sonia Caprio, Md, MD
Pediatric Endocrinology — Payments: $223,374
Pediatric Endocrinology $223,374
Eda Cengiz, M.d, M.D
Pediatric Endocrinology — Payments: $119,501
Pediatric Endocrinology $119,501
Stuart Weinzimer, Md, MD
Pediatric Endocrinology — Payments: $102,508
Pediatric Endocrinology $102,508
Thomas Carpenter, Md, MD
Pediatric Endocrinology — Payments: $87,920
Pediatric Endocrinology $87,920
Dr. Peter Tebben, M.d, M.D
Pediatric Endocrinology — Payments: $3,183
Pediatric Endocrinology $3,183
Michelle Van Name
Pediatric Endocrinology — Payments: $2,395
Pediatric Endocrinology $2,395